73 related articles for article (PubMed ID: 21055454)
1. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.
Salzano G; Marra M; Porru M; Zappavigna S; Abbruzzese A; La Rotonda MI; Leonetti C; Caraglia M; De Rosa G
Int J Pharm; 2011 Jan; 403(1-2):292-7. PubMed ID: 21055454
[TBL] [Abstract][Full Text] [Related]
2. Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model.
Rudnick-Glick S; Corem-Salkmon E; Grinberg I; Margel S
J Nanobiotechnology; 2016 Dec; 14(1):80. PubMed ID: 27919267
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic Acid-containing Nanoparticles With Minimum Premature Release Show Enhanced Activity Against Extraskeletal Tumor.
Li X; Valdes SA; Alzhrani RF; Hufnagel S; Hursting SD; Cui Z
ACS Appl Mater Interfaces; 2019 Feb; 11(7):7311-7319. PubMed ID: 30689348
[TBL] [Abstract][Full Text] [Related]
4. Polymeric Nanoformulation of Zoledronic Acid Rescues Osteoblasts from the Harmful Effect of its Native Form: An In Vitro Investigation of Cytotoxic Potential on Osteoblasts and Osteosarcoma Cells.
Dash P; Samal S; Prasad Panda G; Piras AM; Dash M
Macromol Biosci; 2023 Nov; 23(11):e2300211. PubMed ID: 37384621
[TBL] [Abstract][Full Text] [Related]
5. Coercing bisphosphonates to kill cancer cells with nanoscale coordination polymers.
Liu D; Kramer SA; Huxford-Phillips RC; Wang S; Della Rocca J; Lin W
Chem Commun (Camb); 2012 Mar; 48(21):2668-70. PubMed ID: 22428170
[TBL] [Abstract][Full Text] [Related]
6. Engineering of a New Bisphosphonate Monomer and Nanoparticles of Narrow Size Distribution for Antibacterial Applications.
Tal N; Rudnick-Glick S; Grinberg I; Natan M; Banin E; Margel S
ACS Omega; 2018 Feb; 3(2):1458-1469. PubMed ID: 30023805
[TBL] [Abstract][Full Text] [Related]
7. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.
Marra M; Salzano G; Leonetti C; Porru M; Franco R; Zappavigna S; Liguori G; Botti G; Chieffi P; Lamberti M; Vitale G; Abbruzzese A; La Rotonda MI; De Rosa G; Caraglia M
Biotechnol Adv; 2012; 30(1):302-9. PubMed ID: 21741464
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique.
Schiraldi C; Zappavigna S; D' Agostino A; Porto S; Gaito O; Lusa S; Lamberti M; De Rosa M; De Rosa G; Caraglia M
Cancer Biol Ther; 2014; 15(11):1524-32. PubMed ID: 25482949
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of bisphosphonate and calcium phosphate nanoparticles on peri-implant bone responses in osteoporotic rats.
Alghamdi HS; Bosco R; Both SK; Iafisco M; Leeuwenburgh SC; Jansen JA; van den Beucken JJ
Biomaterials; 2014 Jul; 35(21):5482-90. PubMed ID: 24731712
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes.
Marra M; Salzano G; Leonetti C; Tassone P; Scarsella M; Zappavigna S; Calimeri T; Franco R; Liguori G; Cigliana G; Ascani R; La Rotonda MI; Abbruzzese A; Tagliaferri P; Caraglia M; De Rosa G
Nanomedicine; 2011 Dec; 7(6):955-64. PubMed ID: 21453789
[TBL] [Abstract][Full Text] [Related]
11. Local application of zoledronate inhibits early bone resorption and promotes bone formation.
Hsieh MK; Wang CY; Kao FC; Su HT; Chen MF; Tsai TT; Lai PL
JBMR Plus; 2024 May; 8(5):ziae031. PubMed ID: 38606146
[TBL] [Abstract][Full Text] [Related]
12. Apigenin Loaded Lipoid-PLGA-TPGS Nanoparticles for Colon Cancer Therapy: Characterization, Sustained Release, Cytotoxicity, and Apoptosis Pathways.
Alfaleh MA; Hashem AM; Abujamel TS; Alhakamy NA; Kalam MA; Riadi Y; Md S
Polymers (Basel); 2022 Aug; 14(17):. PubMed ID: 36080654
[TBL] [Abstract][Full Text] [Related]
13. Hybrid Self-Assembling Nanoparticles Encapsulating Zoledronic Acid: A Strategy for Fostering Their Clinical Use.
Abate M; Scotti L; Nele V; Caraglia M; Biondi M; De Rosa G; Leonetti C; Campani V; Zappavigna S; Porru M
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563529
[TBL] [Abstract][Full Text] [Related]
14. Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer.
Li Y; Zhang R; Xu Z; Wang Z
Int J Nanomedicine; 2022; 17():909-925. PubMed ID: 35250267
[TBL] [Abstract][Full Text] [Related]
15. Developing Actively Targeted Nanoparticles to Fight Cancer: Focus on Italian Research.
Argenziano M; Arpicco S; Brusa P; Cavalli R; Chirio D; Dosio F; Gallarate M; Peira E; Stella B; Ugazio E
Pharmaceutics; 2021 Sep; 13(10):. PubMed ID: 34683830
[TBL] [Abstract][Full Text] [Related]
16. The Phospholipid Research Center: Current Research in Phospholipids and Their Use in Drug Delivery.
Drescher S; van Hoogevest P
Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33353254
[TBL] [Abstract][Full Text] [Related]
17. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review.
Wang L; Fang D; Xu J; Luo R
BMC Cancer; 2020 Nov; 20(1):1059. PubMed ID: 33143662
[TBL] [Abstract][Full Text] [Related]
18. Cancer Nanomedicine Special Issue Review Anticancer Drug Delivery with Nanoparticles: Extracellular Vesicles or Synthetic Nanobeads as Therapeutic Tools for Conventional Treatment or Immunotherapy.
Zocchi MR; Tosetti F; Benelli R; Poggi A
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32668783
[TBL] [Abstract][Full Text] [Related]
19. ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma.
Belisario DC; Akman M; Godel M; Campani V; Patrizio MP; Scotti L; Hattinger CM; De Rosa G; Donadelli M; Serra M; Kopecka J; Riganti C
Cells; 2020 Mar; 9(3):. PubMed ID: 32155954
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of RAS: New hope for drugging the "undruggable".
Khan I; Rhett JM; O'Bryan JP
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118570. PubMed ID: 31678118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
